{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:45:59Z","timestamp":1792820759697,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The US President\u2019s Emergency Plan for AIDS Relief (PEPFAR) was launched to increase access to antiretroviral treatment (ART) among people living with HIV (PLHIV) and to prevent new HIV infections globally. As new infections have decreased in many PEPFAR-supported countries, PEPFAR is increasingly focusing on understanding and decreasing mortality among PLHIV, specifically by addressing advanced HIV disease (AHD) and its attendant opportunistic infections (OIs). Several developments in identifying AHD, in preventing, diagnosing, and treating selected OIs, and in PEPFAR\u2019s support for mortality surveillance make this an opportune moment for PEPFAR to address HIV-related mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>AHD upon diagnosis or re-engagement in HIV care is not uncommon, and it substantially increases risk of death from OIs. The World Health Organization provides evidence-based guidelines for a package of interventions for preventing, diagnosing, and treating common OIs, including tuberculosis (TB), cryptococcal meningitis, and severe bacterial infections. PEPFAR facilitates implementation of these guidelines. To identify PLHIV with low CD4, PEPFAR plans to support expanded access to CD4 testing, including a point-of-care assay that differentiates CD4 cell count as a binary of greater than or less than 200 cells\/\u00b5L. To prevent AHD-related mortality, PEPFAR supports rapid ART initiation with integrase inhibitor\u2013based regimens and implementation and documentation of TB preventive treatment. To diagnose selected OIs, PEPFAR is implementing urine lateral flow lipoarabinomannan use to identify TB among PLHIV who have a CD4 cell count\u2009&lt;\u2009200 cells\/\u00b5L. To treat selected OIs, PEPFAR has focused on improving patient-centered care in TB\/HIV co-infection services and scaling up implementation of new drug regimens for cryptococcal meningitis. To better understand mortality, PEPFAR has introduced an indicator, TX_ML, to routinely and systematically categorize outcomes, including deaths, among PLHIV on ART.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PEPFAR is increasing its efforts to identify AHD; to prevent, diagnose, and treat OIs; and to track mortality in its programs. These ongoing efforts, done in collaboration with other stakeholders, seek to decrease mortality among PLHIV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-020-00296-x","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T08:04:00Z","timestamp":1594368240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Addressing advanced HIV disease and mortality in global HIV programming"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-6818","authenticated-orcid":false,"given":"Andrew T.","family":"Boyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikwo","family":"Oboho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Paulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sean Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"296_CR1","unstructured":"PEPFAR. PEPFAR 2020 Country Operational Plan Guidance for all PEPFAR Countries. 2019."},{"key":"296_CR2","unstructured":"PEPFAR 3.0: Controlling the epidemic: Delivering on the promise of an AIDS-free generation [press release]. 2014."},{"key":"296_CR3","unstructured":"PEPFAR Strategy for accelerating HIV\/AIDS epidemic control (2017\u20132020) [press release]. 2017."},{"key":"296_CR4","volume-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. Geneva: World Health Organization; 2017."},{"key":"296_CR5","unstructured":"Global HIV & AIDS statistics 2019 fact sheet [press release]. 2019."},{"issue":"9327","key":"296_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","volume":"360","author":"M Egger","year":"2002","unstructured":"Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119\u201329.","journal-title":"Lancet"},{"issue":"12","key":"296_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/cid\/cis797","volume":"55","author":"AS Walker","year":"2012","unstructured":"Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55(12):1707\u201318.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"296_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/tmi.12746","volume":"21","author":"G Waldrop","year":"2016","unstructured":"Waldrop G, Doherty M, Vitoria M, Ford N. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health. 2016;21(9):1124\u201330.","journal-title":"Trop Med Int Health"},{"issue":"10","key":"296_CR9","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S2352-3018(15)00137-X","volume":"2","author":"N Ford","year":"2015","unstructured":"Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438\u201344.","journal-title":"Lancet HIV."},{"issue":"3","key":"296_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1056\/NEJMe1707598","volume":"377","author":"N Ford","year":"2017","unstructured":"Ford N, Doherty M. The enduring challenge of advanced HIV infection. N Engl J Med. 2017;377(3):283\u20134.","journal-title":"N Engl J Med"},{"issue":"2","key":"296_CR11","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/cid\/ciy045","volume":"66","author":"S Carmona","year":"2018","unstructured":"Carmona S, Bor J, Nattey C, Maughan-Brown B, Maskew M, Fox MP, et al. Persistent high burden of advanced HIV disease among patients seeking care in South Africa\u2019s National HIV Program: data from a Nationwide Laboratory Cohort. Clin Infect Dis. 2018;66(2):S111\u20137.","journal-title":"Clin Infect Dis."},{"key":"296_CR12","unstructured":"PEPFAR. PEPFAR 2019 Country operational plan guidance for all PEPFAR Countries. 2019."},{"issue":"suppl_2","key":"296_CR13","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cix1141","volume":"66","author":"FA Post","year":"2018","unstructured":"Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, et al. Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY Trial. Clin Infect Dis. 2018;66(suppl_2):S132\u20139.","journal-title":"Clin Infect Dis"},{"key":"296_CR14","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019."},{"issue":"15","key":"296_CR15","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/QAD.0000000000000802","volume":"29","author":"RK Gupta","year":"2015","unstructured":"Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987\u20132002.","journal-title":"AIDS."},{"issue":"11","key":"296_CR16","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","volume":"5","author":"A Badje","year":"2017","unstructured":"Badje A, Moh R, Gabillard D, Guehi C, Kabran M, Ntakpe JB, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080\u20139.","journal-title":"Lancet Glob Health."},{"issue":"8","key":"296_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"296_CR18","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/cid\/cix1143","volume":"66","author":"N Ford","year":"2018","unstructured":"Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(2):S152\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"296_CR19","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/S2352-3018(19)30189-4","volume":"6","author":"S Prabhu","year":"2019","unstructured":"Prabhu S, Harwell JI, Kumarasamy N. Advanced HIV: diagnosis, treatment, and prevention. Lancet HIV. 2019;6(8):e540\u201351.","journal-title":"Lancet HIV."},{"issue":"3","key":"296_CR20","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2352-3018(16)30216-8","volume":"4","author":"J O\u2019Connor","year":"2017","unstructured":"O\u2019Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, et al. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per muL: secondary outcome results from a randomised controlled trial. Lancet HIV. 2017;4(3):e105\u201312.","journal-title":"Lancet HIV."},{"issue":"3","key":"296_CR21","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/S2352-3018(16)30213-2","volume":"4","author":"X Anglaret","year":"2017","unstructured":"Anglaret X, Eholie SP. Severe bacterial infections: overlooked opportunistic diseases. Lancet HIV. 2017;4(3):e94\u20135.","journal-title":"Lancet HIV."},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"18932","DOI":"10.7448\/IAS.17.1.18932","volume":"17","author":"C Munthali","year":"2014","unstructured":"Munthali C, Taegtmeyer M, Garner PG, Lalloo DG, Squire SB, Corbett EL, et al. Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2014;17:18932.","journal-title":"J Int AIDS Soc."},{"issue":"3","key":"296_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345.","journal-title":"N Engl J Med"},{"issue":"19","key":"296_CR24","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318.","journal-title":"N Engl J Med"},{"issue":"9936","key":"296_CR25","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48\u00a0week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222\u201331.","journal-title":"Lancet"},{"issue":"1","key":"296_CR26","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/QAI.0000000000001397","volume":"76","author":"M Dutertre","year":"2017","unstructured":"Dutertre M, Cuzin L, Demonchy E, Pugliese P, Joly V, Valantin MA, et al. Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization. J Acquir Immune Defic Syndr. 2017;76(1):e23\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"296_CR27","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","volume":"30","author":"TR Sterling","year":"2016","unstructured":"Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607\u201315.","journal-title":"AIDS."},{"issue":"11","key":"296_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"9983","key":"296_CR29","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","volume":"385","author":"S Mfinanga","year":"2015","unstructured":"Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173\u201382.","journal-title":"Lancet"},{"issue":"4","key":"296_CR30","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1473-3099(18)30493-6","volume":"19","author":"A Loyse","year":"2019","unstructured":"Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis. 2019;19(4):e143\u20137.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"296_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/ajlm.v6i2.460","volume":"6","author":"I Pathmanathan","year":"2017","unstructured":"Pathmanathan I, Date A, Coggin WL, Nkengasong J, Piatek AS, Alexander H. Rolling out Xpert((R)) MTB\/RIF for TB detection in HIV-infected populations: an opportunity for systems strengthening. Afr J Lab Med. 2017;6(2):1\u20139.","journal-title":"Afr J Lab Med."},{"key":"296_CR32","volume-title":"Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV, Policy update (2019)","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV, Policy update (2019). Geneva: World Health Organization; 2019."},{"issue":"8","key":"296_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1473-3099(19)30001-5","volume":"19","author":"T Broger","year":"2019","unstructured":"Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019;19(8):852\u201361.","journal-title":"Lancet Infect Dis."},{"issue":"2","key":"296_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/cid\/ciy472","volume":"68","author":"CC Moore","year":"2019","unstructured":"Moore CC, Jacob ST, Banura P, Zhang J, Stroup S, Boulware DR, et al. Etiology of sepsis in Uganda using a quantitative polymerase chain reaction-based TaqMan array card. Clin Infect Dis. 2019;68(2):266\u201372.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"296_CR35","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/cid\/ciu191","volume":"58","author":"OK Siddiqi","year":"2014","unstructured":"Siddiqi OK, Ghebremichael M, Dang X, Atadzhanov M, Kaonga P, Khoury MN, et al. Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clin Infect Dis. 2014;58(12):1771\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"296_CR36","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1128\/JCM.00476-17","volume":"55","author":"TR Kozel","year":"2017","unstructured":"Kozel TR, Burnham-Marusich AR. Point-of-care testing for infectious diseases: past, present, and future. J Clin Microbiol. 2017;55(8):2313\u201320.","journal-title":"J Clin Microbiol"},{"key":"296_CR37","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"WHO","year":"2019","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019."},{"issue":"11","key":"296_CR38","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","volume":"378","author":"SF Molloy","year":"2018","unstructured":"Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal combinations for treatment of Cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"296_CR39","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/thoraxjnl-2013-204247","volume":"68","author":"HJ Zar","year":"2013","unstructured":"Zar HJ, Madhi SA, Aston SJ, Gordon SB. Pneumonia in low and middle income countries: progress and challenges. Thorax. 2013;68(11):1052\u20136.","journal-title":"Thorax"},{"key":"296_CR40","first-page":"154","volume":"23","author":"S Walusimbi","year":"2016","unstructured":"Walusimbi S, Semitala F, Bwanga F, Haile M, De Costa A, Davis L, et al. Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB\/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study. Pan Afr Med J. 2016;23:154.","journal-title":"Pan Afr Med J."},{"key":"296_CR41","unstructured":"PEPFAR. Monitoring, evaluation, and reporting indicator reference guide (MER 2.0), Version 2.3. 2018."},{"key":"296_CR42","unstructured":"PEPFAR. Monitoring, evaluation, and reporting indicator reference guide (MER 2.0), Version 2.4. 2019."},{"key":"296_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30164-8","author":"P Vizcarra","year":"2020","unstructured":"Vizcarra P, Perez-Elias MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020. https:\/\/doi.org\/10.1016\/S2352-3018(20)30164-8.","journal-title":"Lancet HIV."},{"key":"296_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25955","author":"O Altuntas Aydin","year":"2020","unstructured":"Altuntas Aydin O, Kumbasar Karaosmanoglu H, Kart Yasar K. HIV\/SARS-CoV-2 coinfected patients in Istanbul. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25955.","journal-title":"J Med Virol."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-020-00296-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:15:11Z","timestamp":1625876111000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00296-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00296-x","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}